Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.75 |
| ▸ | ALK | Q9UM73 | 10/20 | 0.69 |
| ▸ | INSR | P06213 | 8/20 | 0.69 |
| ▸ | IGF1R | P08069 | 8/20 | 0.69 |
| ▸ | MET | P08581 | 3/20 | 0.66 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.64 |
| ▸ | AURKA | O14965 | 2/20 | 0.64 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.64 |
| ▸ | JAK2 | O60674 | 2/20 | 0.64 |
| ▸ | STK10 | O94804 | 2/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.64 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.64 |
| ▸ | ABL1 | P00519 | 2/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.64 |
| ▸ | LCK | P06239 | 2/20 | 0.64 |
| ▸ | FYN | P06241 | 2/20 | 0.64 |
| ▸ | FES | P07332 | 2/20 | 0.64 |
| ▸ | CSF1R | P07333 | 2/20 | 0.64 |
| ▸ | YES1 | P07947 | 2/20 | 0.64 |
| ▸ | LYN | P07948 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27076084 | 1.00 | EGFR (0.75) | EGFRALKINSRIGF1RMET | |
| SCHEMBL24992286 | 0.89 | EGFR (0.75) | EGFRALKINSRIGF1RMET | |
| SCHEMBL26906519 | 0.86 | EGFR (0.77) | EGFRALKINSRIGF1RMET | |
| SCHEMBL26906894 | 0.86 | EGFR (0.86) | EGFRALKINSRIGF1RMET | |
| SCHEMBL21846986 | 0.86 | EGFR (1.00) | EGFRALKINSRIGF1RMET | |
| SCHEMBL29904660 | 0.86 | EGFR (0.76) | EGFRALKINSRIGF1RMET | |
| SCHEMBL26906933 | 0.86 | EGFR (0.76) | EGFRALKINSRIGF1RMET | |
| SCHEMBL27075991 | 0.85 | EGFR (0.61) | EGFRALKINSRIGF1RMET | |
| SCHEMBL30014736 | 0.85 | EGFR (0.61) | EGFRALKINSRIGF1RMET | |
| SCHEMBL26906684 | 0.85 | EGFR (0.87) | EGFRALKINSRIGF1RMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297194-B2 | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof | Bridge Biotherapeutics, Inc. (KR) | 2025-05-13 | — | — | US | disclosed |
| US-20220332711-A1 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | Bridge Biotherapeutics, Inc. (KR) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297194-B2 | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof | EGFR, ERBB2, ERBB4 | EGFR 1/4885ALK 90/4885INSR 1593/4885 |
| US-20220332711-A1 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885ALK 90/4885INSR 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.